Response to mepolizumab treatment is sustained across 4-weekly dosing periods

BACKGROUND: Mepolizumab (100 mg delivered s.c. every 4 weeks) is indicated for add-on maintenance treatment for patients with severe eosinophilic asthma. Mepolizumab has been shown to reduce exacerbations and the requirement for daily oral corticosteroids, and improve asthma control and symptoms. Ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Pavord, Ian D., Bleecker, Eugene R., Buhl, Roland, Chanez, Pascal, Bel, Elisabeth H., Howarth, Peter, Bratton, Daniel J., Albers, Frank C., Yancey, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487353/
https://www.ncbi.nlm.nih.gov/pubmed/32963999
http://dx.doi.org/10.1183/23120541.00068-2020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487353/
https://www.ncbi.nlm.nih.gov/pubmed/32963999
http://dx.doi.org/10.1183/23120541.00068-2020

Ejemplares similares